Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05672888

Enrollment

Registered

2023-01-05

Start date

2023-03-31

Completion date

2024-05-31

Last updated

2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pneumonia

Keywords

Pneumonia, COVID-19 Infection

Brief summary

This was a randomized, double-blind, placebo-controlled parallel study.

Interventions

DRUGJaktinib

100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.

DRUGPlacebo

Placebo (given as two placebo tablets) administered orally BID with best available treatment.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years of age, male or female; * History of COVID-19 infection within 1 week; * Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and meeting any of the following criteria: With fever, respiratory symptoms; Shortness of breath present,RR ≥30 breaths/min. * Clear consciousness, Capable and voluntary informed consent.

Exclusion criteria

* Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of the same class, or their excipients, Patients with severe gastrointestinal dysfunction affecting drug absorption; * Any person meeting criteria for critical pneumonia; * Patients considered unsuitable for this trial by the investigator.

Design outcomes

Primary

Measure	Time frame	Description
Time to Recovery	Day 1 to Day 28	Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. NIAID-OS: 1 Not hospitalized, no limitations on activities. 2 Not hospitalized, limitation on activities and/or requiring home oxygen. 3 Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care.

Secondary

Measure	Time frame	Description
Percentage of participants who require invasive mechanical ventilation due to disease progression at Day 3, 7, 1 4 or EOT	Day 3, 7, 14 or EOT	—
Mortality	Day 1 to Day 28	Proportion of patients with all-cause mortality at Day 28

Countries

China

Contacts

Primary ContactJianya Zhou

zhoujianya@hotmail.com0571-87235114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026